Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.

By Xiao-jun Wang, Zheng Sun, N. Villeneuve, Shirley Zhang, Fei Zhao, Yanjie Li, Weimin Chen, X. Yi, Wenxin Zheng, G. Wondrak and 2 more. Carcinogenesis, 2008

832 citations recorded by the source corpus.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/583ea32b70786370de5749251dd2c8924653ffd7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Nrf2:INrf2(Keap1) Signaling in Oxidative Stress (2009, positive): “The loss of INrf2 (Keap1) function has been shown to lead to nuclear accumulation of Nrf2, activation of metabolizing enzymes, and drug resistance [95].”
Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy (2012, background): “Inversely, downregulation of the Nrf2-dependent response by overexpression of Keap1 or transient transfection of Nrf2small interfering RNA (siRNA) rendered cancer cells more susceptible to these drugs [213].”
Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. (2009, methodology): “Total mRNA extraction and qRT-PCR analysis were performed as described in the Supplemental Data and were reported previously (Wang et al., 2008).”
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism (2011, methodology): “Stable knockdown of Nrf2 in A549-K and enhanced susceptibility of this cell line to chemotherapeutic drugs, compared with A549-V, has been reported by our group previously (28).”
Oxidative stress, inflammation, and cancer: how are they linked? (2010, background): “Chemical activation of Nrf2 by pretreatment with tertiary-butylhydroquinone (tBHQ) also increased survival of neuroblastoma cells in response to the three drugs tested [259].”
p62 links autophagy and Nrf2 signaling. (2015, background): “Thus, similar to Nrf2, autophagy plays seemingly contradictory roles in cancer [9,16,17], and the roles of Nrf2 and autophagy in cancer are context-dependent.”
Nrf2, the Master Regulator of Anti-Oxidative Responses (2017, background): “In contrast, the inhibition of Nrf2 by either Keap1 overexpression, Nrf2-small interfering RNA or by an Nrf2 depleting drug leads to anti-cancer drug susceptibility of these cells [115,116].”
Activation of the p62-Keap1-NRF2 Pathway Protects against Ferroptosis in Hepatocellular Carcinoma Cells (2015, background): “NRF2 overexpression inhibits apoptosis and contributes to chemoresistance in several cancers.(11,12) However, it is still unclear whether NRF2 activation is involved in the regulation of other forms of RCD, such as ferroptosis.”
The emerging role of the Nrf2–Keap1 signaling pathway in cancer (2013, background): “Nrf2 has been shown to be constitutively elevated in lung, breast, head and neck, ovarian, and endometrial carcinomas (Singh et al. 2006; Shibata et al. 2008a,b; Wang et al. 2008b; Jiang et al. 2010; Kim et al. 2010; Solis et al. 2010; Zhang et al. 2010).”
The Roles of NRF2 in Modulating Cellular Iron Homeostasis (2017, background): “Additionally, one of the main consequences of constitutive NRF2 activation in tumors is its ability to upregulate cytoprotective genes that rapidly metabolize and eliminate chemotherapeutics and reduce treatment efficacy (160).”
The cytoprotective role of the Keap1–Nrf2 pathway (2011, background): “…that Nrf2 can protect tumours and cell lines from chemotherapeutic drugs, desensitising them to etoposide, carboplatin, cisplatin, doxorubicin, 5-fluorouracil and paclitaxel (Singh et al. 2006; Wang et al. 2008b; Ohta et al. 2008; Shibata et al. 2008a, b; Loignon et al. 2009; Jiang et al. 2010).”